 This is an Investigator-initiated, prospective, open-label, randomized, adaptive design study to enroll 30 adult renal transplant recipients with biopsy-confirmed AMR within 30 days post transplantation. After informed consent is obtained and study eligibility is confirmed, subjects will be enrolled immediately after biopsy confirmation of AMR and positive donor specific antibody DSA. Subjects will then be randomized into one of two treatment groups SOC control or rhC1INH. An initial cohort of 8 subjects 3 SOC, 5 rhC1INH will receive intensive safety monitoring of the coagulation system and for thromboembolic events. 